Leiden, Netherlands

Peter Devilee


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2004-2009

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Peter Devilee: Innovator in Genetic Diagnostics

Introduction

Peter Devilee is a prominent inventor based in Leiden, Netherlands. He has made significant contributions to the field of human genetics, particularly in the area of cancer predisposition testing. With a total of two patents to his name, his work has the potential to impact the diagnosis and prognosis of breast and ovarian cancer.

Latest Patents

Peter Devilee's latest patents focus on a diagnostic test kit designed to determine a predisposition for breast and ovarian cancer. This invention relates to the detection of specific germline mutations in the BRCA1 gene, which are known to increase the risk of these cancers. The patent details the molecular genetic mechanisms that may have contributed to the genesis of these mutations, emphasizing the role of Alu repetitive DNA elements found in the intronic regions of the BRCA1 gene. Furthermore, the invention addresses somatic mutations in the BRCA1 gene and their relevance in diagnosing and prognosing human breast and ovarian cancer. The screening of these BRCA1 mutations in human genomic DNA is particularly useful for identifying inherited predispositions to these cancers.

Career Highlights

Peter Devilee is affiliated with Rijksuniversiteit Te Leiden, where he continues to advance research in genetics and cancer diagnostics. His work has garnered attention for its innovative approach to understanding genetic predispositions and their implications for patient care.

Collaborations

Peter has collaborated with notable colleagues such as Garrit-Jan Boudewijn Van Ommen and Anne Petrij-Bos. Their combined expertise has contributed to the development of groundbreaking research in the field of human genetics.

Conclusion

Peter Devilee's contributions to genetic diagnostics, particularly in relation to breast and ovarian cancer, highlight the importance of innovation in medical research. His patents reflect a commitment to improving diagnostic methods and understanding genetic predispositions, ultimately benefiting patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…